Bomedmestat (USAN; IUPAC name N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide) is an investigational drug under development by Imago BioSciences for the treatment of myeloproliferative neoplasms including essential thrombocythemia, polycythemia vera, myelofibrosis[1] and small-cell lung cancer.[2]
^"Bomedemstat". PubChem. U.S. National Library of Medicine.
^"A Phase I/II Study of Bomedemstat Combined With Maintenance Immunotherapy for Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC)". clinicaltrials.gov. 2 May 2024. Retrieved 12 May 2024.
acquired Imago BioSciences with the rights to develop bomedemstat in January 2023. Bomedemstat was developed to inhibit the human enzyme lysine-specific...
method is pharmacologic inhibition of LSD1; many such inhibitors such as bomedemstat do not abrogate the scaffold function of LSD1 but rather inhibit the...
clinical trials (NCT04254978) are agents that lower platelets such as bomedemstat. Hydroxycarbamide, interferon-α and anagrelide can lower the platelet...